BioMarin Pharmaceutical Inc.

Biomirin | December 14, 2016

BlackRock Advisors LLC reduced its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 98.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 358,973 shares of the company’s stock after selling 27,783,688 shares during the period. BlackRock Advisors LLC owned about 0.21% of BioMarin Pharmaceutical worth $33,213,000 at the end of the most recent quarter....

The Cerbat Gem | December 28, 2016

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday. The brokerage currently has a $95.00 price target on the stock. Zacks Investment Research’s target price points to a potential upside of 11.66% from the company’s previous close....

Business Insights

BioMarin Pharmaceutical Inc. | November 24, 2022

BioMarin Pharmaceutical Inc. announced advancements in the U.S. Food and Drug Administration review of the Biologics License Application of ROCTAVIAN™ for adults with severe hemophilia A. The Company was recently notified by the FDA that after further consideration, at this time, the Agency no longer plans to hold an advisory committee meeting to discuss the BLA for ROCTAVIAN that is currently under review. Previously, the FDA communicated to the Company that it did intend to hold an...

Pharma Tech

BioMarin Pharmaceutical Inc. | March 08, 2023

On March 7, 2023, BioMarin Pharmaceutical Inc., a global biotech company focused on improving lives via genetic discovery, announced that the US FDA has accepted its supplemental New Drug Application (sNDA) for VOXZOGO® (vosoritide) for injection to expand the treatment of achondroplasia in children under the age of 5. Achondroplasia is a common form of disproportionate short stature. The FDA has set an action date of October 21, 2023, for the sNDA. The sNDA is supported by ...